Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.66 USD | -2.38% | -1.83% | +25.07% |
Financials (USD)
Sales 2024 * | 162M | Sales 2025 * | 293M | Capitalization | 1.6B |
---|---|---|---|---|---|
Net income 2024 * | -31M | Net income 2025 * | 91M | EV / Sales 2024 * | 9.7 x |
Net cash position 2024 * | 27.06M | Net cash position 2025 * | 95.46M | EV / Sales 2025 * | 5.13 x |
P/E ratio 2024 * |
-255
x | P/E ratio 2025 * |
7.2
x | Employees | 154 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.1% |
Latest transcript on Avadel Pharmaceuticals plc
1 day | -2.38% | ||
1 week | -1.83% |
Managers | Title | Age | Since |
---|---|---|---|
Gregory Divis
CEO | Chief Executive Officer | 57 | 17-01-02 |
Thomas McHugh
DFI | Director of Finance/CFO | 59 | 19-12-01 |
Scott Macke
COO | Chief Operating Officer | - | 14-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Eric Ende
BRD | Director/Board Member | 55 | 18-11-30 |
Gregory Divis
CEO | Chief Executive Officer | 57 | 17-01-02 |
Mark McCamish
BRD | Director/Board Member | 72 | 19-12-04 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 17.66 | -2.38% | 444,065 |
24-04-23 | 18.09 | +4.57% | 985,700 |
24-04-22 | 17.3 | -0.17% | 823,511 |
24-04-19 | 17.33 | -0.29% | 1,332,519 |
24-04-18 | 17.38 | -3.39% | 1,108,188 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.07% | 1.6B | |
+25.61% | 660B | |
+25.87% | 562B | |
-5.24% | 358B | |
+16.49% | 322B | |
+8.28% | 297B | |
+7.09% | 219B | |
-9.12% | 196B | |
+5.01% | 199B | |
-8.75% | 149B |
- Stock Market
- Equities
- AVDL Stock